SCV
IKT icon

Sands Capital Ventures’s Inhibikase Therapeutics IKT Stock Holding History

Sands Capital Ventures’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Hold
13,018,965
– – 4.31% 6
2026
Q1 		$21.9M Hold
13,018,965
– – 5.19% 5
2025
Q4 		$26.7M Buy
13,018,965
+2,068,965
+19% +$3.29M 5.15% 4
2025
Q3 		$17.7M Hold
10,950,000
– – 3.89% 7
2025
Q2 		$21.4M Hold
10,950,000
– – 4.2% 6
2025
Q1 		$24M Hold
10,950,000
– – 5.86% 5
2024
Q4 		$35.6M Buy
+10,950,000
New +$27.3M 7.74% 4

Other funds holding IKT

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Sands Capital Ventures's IKT Position: Q2 2026 in Review

Sands Capital Ventures held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 13,018,965 shares worth $26.4M. The position accounts for 4.31% of the portfolio, ranked #6.

Sands Capital Ventures first reported a position in IKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $35.6M in Q4 2024. 98 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Sands Capital Ventures held 13,018,965 shares of Inhibikase Therapeutics worth $26.4M as of Q2 2026.
  • Sands Capital Ventures left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up 4.31% of Sands Capital Ventures's portfolio in Q2 2026, its #6 holding.
  • Sands Capital Ventures first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Sands Capital Ventures's Inhibikase Therapeutics position peaked at $35.6M in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.